Exhibit 99.1


  CardioDynamics Appoints Ronald L. Merriman to Board of Directors;

          Financial Leader with over 30 Years of Experience
                    in Healthcare & Life Sciences


    SAN DIEGO--(BUSINESS WIRE)--July 21, 2003--CardioDynamics
(Nasdaq:CDIC), the innovator and leader of Impedance Cardiography
(ICG) technology and manufacturer of BioZ(R) noninvasive cardiac
function monitoring systems, today announced the appointment of Ronald
L. Merriman to the company's Board of Directors at its Annual
Shareholders Meeting held July 17, 2003.
    Merriman, who qualifies as an independent director under Nasdaq
rules and as a financial expert under the Sarbanes-Oxley Act of 2002,
will also serve as chairman of the company's Audit Committee.
    Merriman, a certified public accountant, recently served as
managing director of the international law firm, O'Melveny & Myers
LLP. Merriman retired in 1997 as vice chair of the Big Four global
accounting firm, KPMG, following a 30-year career. He worked
extensively with Fortune 500 companies' boards of directors, audit
committees and senior management. Merriman was the senior partner in
charge of KPMG's healthcare and life science sector, one of KPMG's
five global business segments. Merriman was also a member of KPMG's
management committee and served on the leadership team that
repositioned KPMG to achieve record growth and profitability.
    "We are excited to have Ron join our Board of Directors," stated
Michael K. Perry, chief executive officer of CardioDynamics. "In light
of the current legislative initiatives regarding corporate governance,
the addition of a seasoned director with a public accountancy
background to our Audit Committee and Board further enhances our
commitment to our shareholders. With Ron's extensive experience and
track record of success, his appointment will add depth to our
talented and exceptionally strong Board."

    About CardioDynamics:

    CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator
and leader of breakthrough medical technology called Impedance
Cardiography (ICG). The company's BioZ(R) Systems are being used by
leading physicians around the world to help battle the number one
killer of men and women -- cardiovascular disease. Partners include GE
Medical Systems Information Technologies, Philips Medical Systems, and
Vasomedical. The worldwide market potential for BioZ products is
estimated to be $5 billion and an additional $800 million in recurring
annual revenue for disposables. For additional information or to
request an investor package, refer to the company's Web site at
www.cdic.com.

    Forward-Looking (Safe Harbor) Statement:

    Except for the historical and factual information contained
herein, this press release contains forward-looking statements, such
market size, potential, growth and penetration rates, the accuracy of
which is necessarily subject to uncertainties and risks including the
company's sole dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as
other risks detailed in the company's filings with the SEC, including
its 2002 Form 10-K. The company does not undertake to update the
disclosures contained in this press release.



    CONTACT: CardioDynamics
             Bonnie Ortega, 888-522-2342, Ext. 1005 (Investors)
             bortega@cardiodynamics.com
                 or
             Irene Paigah, 888-522-2342, Ext. 1012 (Media)
             ipaigah@cardiodynamics.com